Demographic and clinical variables | Hospitalization within the last 30 days of life | ||
---|---|---|---|
Yes | No | ||
n = 272 (%) | n = 111 (%) | p | |
Gender | |||
Male | 178 (65%) | 59 (53%) | 0.025 |
Female | 94 (35%) | 52 (47%) | |
Age at death (years) | |||
Mean | 70 | 73 | 0.150 |
Median | 72 | 74 | |
Patients with minor children | |||
Yes | 21 (8%) | 8 (7%) | 0.863 |
No | 251 (92%) | 103 (93%) | |
Primary malignancy | |||
Colorectal | 52 | 30 | |
Pancreatic | 42 | 13 | |
Prostate | 40 | 14 | |
Breast | 24 | 17 | |
Urothelial | 18 | 5 | |
Bile duct | 17 | 5 | |
Kidney | 15 | 9 | |
Malignant melanoma | 15 | 3 | |
Esophageal | 14 | 2 | |
Ventricular | 11 | 6 | |
Hepatic | 8 | 0 | |
Cancer of unknown primary cite | 6 | 5 | |
Others | 10g | 2h | |
Multiple primary malignancies | |||
Yes | 13 (5%) | 10 (9%) | 0.114 |
No | 259 (95%) | 101 (90%) | |
Anticancer treatment linesi | |||
Never treated | 67 (25%) | 41 (37%) | 0.015 |
Treated | 205 (75%) | 70 (63%) | |
One line | 79 | 38 | |
Two lines | 62 | 10 | |
Three lines | 24 | 8 | |
Four lines or greater | 40 | 14 | |
Anticancer treatment within the last 30 DOLj | |||
No | 168 (62%) | 86 (77%) | 0.003 |
Yes | 104 (38%) | 25 (23%) | |
Chemotherapy | 30ab | 2 | |
Targeted therapy | 22acd | 2f | |
Check-point-inhibitors | 3 | 1 | |
Endocrine therapy | 46bce | 21 | |
Radiation therapy | 18cde | 0 | |
Palliative care unit referral | |||
Yes | 184 (68%) | 79 (71%) | 0.500 |
No | 88 (32%) | 32 (29%) | |
Interval from PCU referral until death | |||
Mean (days) | 99 | 181 | < 0.001 |
Median (days) | 57 | 102 | |
Use of PCU within the last 30 DOLj | |||
Yes | 155 (57%) | 46 (41%) | 0.006 |
No | 117 (43%) | 65 (59%) | |
Interval from diagnosis until death | |||
Mean (days) | 677 | 763 | 0.471 |
Median (days) | 275 | 326 |